Back to top
more

VIVUS, Inc. (VVUS)

(Delayed Data from NSDQ)

$3.73 USD

3.73
58,550

+0.03 (0.81%)

Updated May 3, 2019 04:13 PM ET

After-Market: $3.83 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label

by Zacks Equity Research

Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion of its colorectal cancer drug, Vectibix.

    Roche's (RHHBY) Leukemia Drug Gets Prime Status in EU

    by Zacks Equity Research

    Roche (RHHBY) announced that its investigational drug polatuzumab vedot in combination with MabThera and bendamustine was granted prime status in the EU.

      Acorda Files NDA for Parkinson's Disease Candidate Inbrija

      by Zacks Equity Research

      Acorda Therapeutics, Inc. (ACOR) has submitted a new drug application to FDA for its late stage pipeline candidate Inbrija for treatment of patients suffering from Parkinson's disease.

        Valeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA

        by Zacks Equity Research

        Valeant Pharmaceuticals International, Inc.'s (VRX) wholly owned subsidiary, Salix Pharmaceuticals, announced that the FDA has accepted its New Drug Application for Plenvu.

          KemPharm (KMPH) Strengthens its ADHD Prodrug Pipeline

          by Zacks Equity Research

          KemPharm, Inc. (KMPH) announced that it has strengthened its attention deficit hyperactivity disorder (ADHD) produg pipeline portfolio.

            Neothetics' Fat Reduction Candidate Fails in Phase II Study

            by Zacks Equity Research

            Neothetics, Inc. (NEOT) announced disappointing top line results from a phase II proof-of-concept study, LIPO-202-CL-31, evaluating its lead candidate, LIPO-202, for reduction of submental subcutaneous fat.

              Why is Catalyst Pharmaceuticals' Stock Up 160% this Year?

              by Zacks Equity Research

              Shares of Catalyst Pharmaceuticals, Inc. (CPRX) have soared 161% this year so far, massively outperforming the Zacks classified Medical Drugs industry's gain of 10.2%.

                Teva/Xenon Nerve Pain Candidate Fails in Phase II Study

                by Zacks Equity Research

                Teva Pharmaceutical Industries Ltd. (TEVA) announced that a mid-stage study evaluating their pipeline candidate, topical TV-45070 for post-herpetic neuralgia (PNH) did not meet the primary endpoint.

                  Seattle Genetics (SGEN) Reports Positive Data for Adcetris

                  by Zacks Equity Research

                  Seattle Genetics, Inc. (SGEN) and partner Takeda Pharmaceutical Company Limited announced positive results from phase III study, ECHLEON 1 study.

                    Bristol-Myers Reports Data on Immuno-Oncology Drug Empliciti

                    by Zacks Equity Research

                    Bristol-Myers Squibb Company (BMY) announced four-year follow-up data from the phase III study, ELOQUENT-2 on immuno-oncology Empliciti.

                      Here's Why Investors Are Glued to Vertex Pharma (VRTX) Stock

                      by Zacks Equity Research

                      Vertex Pharmaceuticals, Inc. (VRTX), has been attracting investor attention.

                        Regeneron (REGN) Stock on Fire: What's Behind the Surge?

                        by Zacks Equity Research

                        Shares of Regeneron Pharmaceuticals, Inc. (REGN) have moved up 14.8% over the last 30 days.

                          Shire (SHPG) Receives MAA Validation for Veyvondi by EMA

                          by Zacks Equity Research

                          Shire plc (SHPG) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for Veyvondi to prevent and treat bleeding episodes and peri-operative bleeding in adults diagnosed with von Willebrand Disease.

                            Here's Why Geron (GERN) is a Good Stock to Invest in Now

                            by Zacks Equity Research

                            Geron Corporation (GERN) is developing anti-cancer therapies based on telomerase inhibitors.

                              Glaxo's (GSK) Shingles Candidate Phase III Data Positive

                              by Zacks Equity Research

                              GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.

                                Indivor's Opioid Use Disorder Drug Meets Primary Endpoint

                                by Zacks Equity Research

                                Indivior PLC (INVVY) announced that a pivotal study (RB-US-13-0001) evaluating its candidate, RBP-6000, in patients with moderate-to-severe opioid use disorder (OUD) met its primary endpoint.

                                  Novartis Announces Positive Results for Cardiovascular Drug

                                  by Zacks Equity Research

                                  Novartis AG (NVS) announced top-line results from the global phase III study, CANTOS on cardiovascular drug.

                                    BioMarin (BMRN) in Focus: Stock Moves 7% Higher

                                    by Zacks Equity Research

                                    BioMarin (BMRN) was a big mover last session, as the company saw its shares rise 7% on the day.

                                      Myriad Genetics (MYGN) Catches Eye: Stock Moves Up 5.7%

                                      by Zacks Equity Research

                                      Myriad Genetics, Inc. (MYGN) moved big last session, as its shares rose over 5% on the day.

                                        Novartis Migraine Drug Accepted, AMD Positive in Phase III

                                        by Zacks Equity Research

                                        Novartis (NVS) announced that the EMA accepted its application for migraine candidate AMG 334.

                                          Seattle Genetics (SGEN) Submits BLA to FDA for Cancer Drug

                                          by Zacks Equity Research

                                          Seattle Genetics, Inc. (SGEN) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA for Adcetris (brentuximab vedotin) in patients with cutaneous T-cell lymphoma (CTCL).

                                            Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US

                                            by Zacks Equity Research

                                            Shire Plc (SHPG) announced that the FDA has approved its new attention deficit hyperactivity disorder (ADHD) drug, Mydayis (mixed salts of a single-entity amphetamine product) in patients 13 years and older

                                              Agenus (AGEN) Looks Good: Stock Moves Up 9.6% in Session

                                              by Zacks Equity Research

                                              Agenus Inc. (AGEN) moved big last session, as its shares rose almost 10% on the day.

                                                Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada

                                                by Zacks Equity Research

                                                Health Canada granted a Notice of Compliance (NOC) for Vemlidy 25mg tablets, a once-daily treatment for adults with chronic HBV infection with compensated liver disease.

                                                  Horizon Pharma Gets Health Canada Approval for Procysbi

                                                  by Zacks Equity Research

                                                  Horizon Pharma plc (HZNP), announced that it has received approval in Canada for Procysbi (cysteamine delayed-release capsules) for the treatment of nephropathic cystinosis in adults and children of 2 years old and more.